Brief: Arvinas And Pfizer Announce Initial Phase 1B Data From The Tactive-U Sub-Study Of Vepdegestrant In Combination With Abemaciclib At 2024 San Antonio Breast Cancer Symposium

Arvinas

10/12/2024 14:07

Dec 10 (Reuters) - Arvinas  ARVN.O :
    * ARVINAS AND PFIZER ANNOUNCE INITIAL PHASE 1B DATA FROM THE
TACTIVE-U SUB-STUDY OF VEPDEGESTRANT IN COMBINATION WITH
ABEMACICLIB AT 2024 SAN ANTONIO BREAST CANCER SYMPOSIUM
    * ARVINAS INC - VEPDEGESTRANT AND ABEMACICLIB SHOW 62.5%
CLINICAL
BENEFIT RATE
    * ARVINAS INC - COMBINATION SHOWS CONSISTENT SAFETY PROFILE,
NO
SIGNIFICANT DRUG INTERACTION
    * ARVINAS INC - RECOMMENDED PHASE 2 DOSE IS 200 MG QD
VEPDEGESTRANT, 150 MG BID ABEMACICLIB

Source text:  ID:nGNX7Wzvky 
Further company coverage:  ARVN.O 

 ((Reuters.Briefs@thomsonreuters.com;))